Open Access, Peer-reviewed
eISSN 2288-338X
    Korean J Adult Nurs. 2016 Jun;28(3):343-353. English.
    Published online Jun 30, 2016.
    https://doi.org/10.7475/kjan.2016.28.3.343
    © 2016 Korean Society of Adult Nursing
    Original Article

    Oxaliplatin-Induced Peripheral Neuropathy and Quality of Life in Patients with Digestive System Cancer

    Hye Young Kim
      • College of Nursing, Research Institute of Nursing Science, Chonbuk National University, Jeonju, Korea.
    • Corresponding author: Kim, Hye Young. College of Nursing, Research Institute of Nursing Science, Chonbuk National University, 567 Baekje-daero, deokjin-gu, Jeonju 54896, Korea. Tel: +82-63-270-4618, Fax: +82-82-63-270-3127, Email: tcellkim@jbnu.ac.kr
    Received March 29, 2016; Revised May 20, 2016; Accepted June 20, 2016.

    This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Abstract

    Purpose

    This study aimed to identify the levels of oxaliplatin-induced peripheral neuropathy (OXLIPN) and the quality of life (QOL) related to OXLIPN in patients with digestive system cancer.

    Methods

    A total of 83 patients with chemotherapy-induced peripheral neuropathy (CIPN)-related symptoms participated in this study. Data were collected through self-reported questionnaire which were constructed to include general and clinical characteristics, EORTC QLQ-C30, Patient Neurotoxicity Questionnaire (PNQ), and EORTC QLQ-CIPN20.

    Results

    The average scores of OXLIPN upper and lower extremity scale were 30.01 and 29.16, respectively. The average scores of PNQ sensory and motor scale were 2.11 and 1.70, respectively. The mean score of the QLQ-C30 global health status was 54.85, and the range of mean score of the functional and symptom subdomains was 34.85~73.29 and 17.67~53.54, respectively. The CIPN-related symptoms positively correlated with the global health status scale and all subdomains of functional scale, respectively and negatively correlated with fatigue, pain, dyspnea, insomnia, and financial problem subdomains of the symptom scale, respectively.

    Conclusion

    Oncology nurses should pay attention and provide remedies for CIPN symptoms reported by their patients. Nursing interventions should be developed for patients with digestive system cancer to alleviate CIPN and enhance their QOL.

    Keywords
    Quality of life; Chemotherapy; Peripheral neuropathies; Digestive system neoplasms

    Tables

    Table 1
    Mean Differences in OXLIPN according to General and Clinical Characteristics (N=83)

    Table 2
    Participants Reporting “quite a bit” or “very much” on 16-item QLQ-CIPN20 and Neurotoxic Events graded by PNQ (N=83)

    Table 3
    Participants' Level of 16-item QLQ-CIPN20, PNQ and EORTC QLQ-C30 (N=83)

    Table 4
    Correlation among the 16-item QLQ-CIPN20 Subscales, PNQ Subscales, and Health-related QOL (N=83)

    References

      1. Sasane M, Tencer T, French A, Maro T, Beusterien KM. Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: A review. J Support Oncol 2010;8(6):e15–e21. [doi: 10.1016/j.suponc.2010.09.029]
      1. Kim HY, Kang JH, Song CE, Youn HJ. Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Breast Cancer Patients. Asian Oncol Nurs 2013;13(4):222–230. [doi: 10.5388/aon.2013.13.4.222]
      1. Woo IS. Recent updates on chemotherapy-induced peripheral neuropathy. Korean J Med 2015;88(1):35–37. [doi: 10.3904/kjm.2015.88.1.35]
      1. Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: differential diagnosis and management. Am Fam Physician 2010;81(7):887–892.
      1. Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 2010;14(3):E22–E28. [doi: 10.1188/10.CJON.E22-E28]
      1. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 2006;4:398–399.
      1. Song CE, Kim HY, Lee ES. Relationship between chemotherapy-induced peripheral neuropathy and quality of life in patients with hematological malignancies. Korean J Adult Nurs 2015;27(3):358–366. [doi: 10.7475/kjan.2015.27.3.358]
      1. Jung SH, Kim SH, Kim JH. Clinical correlation between in vitro chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients. Korean J Clin Oncol 2015;11:51–58. [doi: 10.14216/kjco.15010]
      1. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20(23):4543–4548.
      1. Kim H. Adjuvant chemotherapy in colorectal cancer. Korean J Clin Oncol 2008;4(2):42–47.
      1. Tofthagen C, McAllister R, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs 2011;15(2):182–188. [doi: 10.1188/11.CJON.182-188]
      1. Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs 2011;11(3):254–262. [doi: 10.5388/jkon.2011.11.3.254]
      1. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011;19(6):833–841. [doi: 10.1007/s00520-010-0911-0]
      1. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs 2010;10(2):231–239. [doi: 10.5388/jkon.2010.10.2.231]
      1. Kato J, Nagahara A, Iijima K, Yoshimura M, Osada T, Yoshizawa T, Watanabe S. Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan. J Gastroenterol Hepatol 2008;23 Suppl 2:S268–SS72. [doi: 10.1111/j.1440-1746.2008.05414.x]
      1. Kim HY, Kang JH, Youn HJ, So HS, Song CE, Chae SY, et al. Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy. J Korean Acad Nurs 2014;44(6):735–742. [doi: 10.4040/jkan.2014.44.6.735]
      1. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009;41(4):1149–1160. [doi: 10.3758/BRM.41.4.1149]
      1. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359–1367. [doi: 10.1001/jama.2013.2813]
      1. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 2009;17(12):1483–1491. [doi: 10.1007/s00520-009-0613-7]
      1. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 2005;41(8):1135–1139.
      1. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. In: The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001.
      1. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004;13(4):863–868.
      1. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN instrument, N06CA. Support Care Cancer 2012;20(3):625–632. [doi: 10.1007/s00520-011-1141-9]
      1. Wickham R. chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs 2007;11:361–376. [doi: 10.1188/07.CJON.361-376]
      1. Yoon WK, Heo MJ, Lee OS, Lim SC. Evaluation of chemotherapy induced peripheral neuropathy by cisplatin, carboplatin and oxaliplatin. Korean J Clin Pharm 2012;22(4):356–366.
      1. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2005;32(2):305–311. [doi: 10.1188/05.ONF.305-311]
      1. Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 2007;56(5):323–331. [doi: 10.1097/01.NNR.0000289503.22414.79]
      1. Javier NS, Montagnini ML. Rehabilitation of the hospice and palliative care patient. J Palliat Med 2011;14(5):638–648. [doi: 10.1089/jpm.2010.0125]
      1. Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol 2012;30(30):3687–3696. [doi: 10.1200/JCO.2012.41.7238]
    MeSH Terms
    Digestive System Neoplasms*
    Digestive System*
    Drug Therapy
    Dyspnea
    Fatigue
    Global Health
    Humans
    Lower Extremity
    Nursing
    Peripheral Nervous System Diseases*
    Quality of Life*
    Sleep Initiation and Maintenance Disorders
    Metrics
    Share
    Tables
    slide
    slide
    slide
    slide

    1 / 4

    PERMALINK